| 0.5001 -0.046 (-8.41%) | 10-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.74 |
1-year : | 0.87 |
| Resists | First : | 0.63 |
Second : | 0.74 |
| Pivot price | 0.63 |
|||
| Supports | First : | 0.45 |
Second : | 0.38 |
| MAs | MA(5) : | 0.56 |
MA(20) : | 0.63 |
| MA(100) : | 0.69 |
MA(250) : | 0.86 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 12.9 |
D(3) : | 18.7 |
| RSI | RSI(14): 30.7 |
|||
| 52-week | High : | 1.55 | Low : | 0.45 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NAOV ] has closed below the lower bollinger band by 2.7%. Bollinger Bands are 71.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.54 - 0.54 | 0.54 - 0.55 |
| Low: | 0.45 - 0.46 | 0.46 - 0.46 |
| Close: | 0.49 - 0.5 | 0.5 - 0.51 |
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.
Mon, 23 Sep 2024
NAOV - NanoVibronix, Inc. Latest Stock News & Market Updates - StockTitan
Mon, 23 Sep 2024
NanoVibronix Signs Letter of Intent with Potential New Distributor - StockTitan
Thu, 16 May 2024
NanoVibronix Issues Letter to Stockholders - Yahoo Finance
Tue, 14 May 2024
NanoVibronix Announces Distribution Agreement with VA Supplier CB Medical for the Distribution of UroShield - Business Wire
Wed, 06 Dec 2023
NanoVibronix Featured in Your Bladder Health Magazine - Business Wire
Wed, 23 Aug 2023
NanoVibronix Extends Distribution Agreement with Its Largest Distributor for PainShield and PainShield Plus - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 3 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 8.3 (%) |
| Shares Short | 40 (K) |
| Shares Short P.Month | 25 (K) |
| EPS | -1.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.01 |
| Profit Margin | -83.5 % |
| Operating Margin | -82.5 % |
| Return on Assets (ttm) | -29.6 % |
| Return on Equity (ttm) | -140.6 % |
| Qtrly Rev. Growth | 177.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.21 |
| EBITDA (p.s.) | -0.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -2 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -0.39 |
| PEG Ratio | 0 |
| Price to Book value | 0.49 |
| Price to Sales | 0.41 |
| Price to Cash Flow | -0.61 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|